Braziel, Rita M <br/><br/>
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.  [electronic resource] 

 -  Blood  Jul 2002 
 - 435-41 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Standard No.: </label>10.1182/blood.v100.2.435  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Benzamides<br/>Blood Cells--cytology<br/>Bone Marrow Cells--cytology<br/>Cytogenetic Analysis<br/>Drug Resistance<br/>Female<br/>Follow-Up Studies<br/>Fusion Proteins, bcr-abl--analysis<br/>Humans<br/>Imatinib Mesylate<br/>Interferon-alpha--administration & dosage<br/>Karyotyping<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Philadelphia Chromosome<br/>Piperazines--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Remission Induction--methods<br/>Retrospective Studies<br/>Time Factors<br/>Treatment Outcome